Accelerator Technology and Full-Chain Solutions for Diagnostic Radioisotope Production ⚛️

2026-05-19

Radiopharmaceuticals are advancing precision diagnosis and treatment, with diagnostic radioisotopes supporting PET/SPECT imaging, molecular research, and clinical translation.

🏥 Stable supply matters F-18 FDG remains one of the most widely used PET radiopharmaceuticals. For hospitals and regional radiopharmaceutical centers, stable production directly affects examination scheduling, distribution radius, and patient access.

🧪 Beyond F-18 FDG Demand is expanding to C-11, N-13, Ga-68, Cu-64, Zr-89, I-124, In-111, Sc-44 and other diagnostic isotopes. A future-oriented platform should support both routine clinical needs and emerging applications.

⚙️ More than a cyclotron Diagnostic isotope production involves beam generation, target irradiation, isotope transfer, synthesis, purification, dispensing, and quality control. Any mismatch may affect yield, product quality, and operating efficiency.

🔗 Full-chain coordination Target systems, synthesis modules, purification, QC, hot cells, cleanrooms, radiation protection, and personnel flow all influence safe, compliant, and long-term operation.

🏗️ A practical platform choice For PET/SPECT-focused projects, a 20 MeV medical cyclotron offers a balanced solution in isotope coverage, site construction, radiation protection, maintenance, staffing, and project execution.

🌍 LBT’s integrated solution LBT supports diagnostic isotope production with medical cyclotrons, gas/liquid/solid targets, automated synthesis modules, dispensing systems, QC support, site planning, installation, commissioning, training, and long-term service.

🚀 Stable. Compliant. Sustainable. By integrating accelerator technology with full-chain production capabilities, LBT helps nuclear medicine centers and radiopharmaceutical platforms build future-oriented diagnostic isotope supply system